Learning Objectives
- Describe key clinical trial data from 2024 ASH in the management of AML and the potential impact on Canadian practices.
- Discuss the most significant abstracts presented at the 2024 ASH in AML.
- Review the latest advances in the management of AML as they pertain to hematology, transplant, and pathology.
Speakers
Dr. Guillaume Richard-Carpentier (Speaker)
Dr. Christopher Lemieux (Moderator)
This program has been made possible through unrestricted support from Astellas.
